(0.32%) 5 116.34 points
(0.32%) 38 362 points
(0.37%) 15 986 points
(-0.94%) $83.06
(5.36%) $2.03
(0.31%) $2 354.50
(0.44%) $27.66
(4.10%) $959.90
(-0.28%) $0.932
(-0.46%) $10.97
(-0.58%) $0.796
(1.66%) $93.40
@ $1.110
発行日: 14 2月 2024 @ 23:32
リターン: -18.92%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: 2.30 %
Live Chart Being Loaded With Signals
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease...
Stats | |
---|---|
本日の出来高 | 5.16M |
平均出来高 | 4.09M |
時価総額 | 135.91M |
EPS | $0 ( 2024-03-05 ) |
次の収益日 | ( $0 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.010 |
ATR14 | $0.00400 (0.45%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-04 | Graves Kurt | Buy | 60 000 | Stock Option (right to buy) |
2024-04-04 | Kender Richard N | Buy | 60 000 | Stock Option (right to buy) |
2024-04-04 | Biondi Paul | Buy | 60 000 | Stock Option (Right to Buy) |
2024-04-04 | Fraser Claire | Buy | 60 000 | Stock Option (right to buy |
2024-04-04 | Dere Willard H | Buy | 60 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
92.36 |
Last 99 transactions |
Buy: 7 007 921 | Sell: 289 369 |
ボリューム 相関
Seres Therapeutics Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Seres Therapeutics Inc 相関 - 通貨/商品
Seres Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $126.33M |
総利益: | $111.21M (88.04 %) |
EPS: | $-0.890 |
FY | 2023 |
収益: | $126.33M |
総利益: | $111.21M (88.04 %) |
EPS: | $-0.890 |
FY | 2022 |
収益: | $7.13M |
総利益: | $6.12M (85.91 %) |
EPS: | $-2.35 |
FY | 2021 |
収益: | $144.93M |
総利益: | $144.93M (100.00 %) |
EPS: | $-0.720 |
Financial Reports:
No articles found.
Seres Therapeutics Inc
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。